In addition, although parental DLBCL lines with TP53 mutations (e.g., SUDHL4, SUDHL6, and SUDHL16) were not more resistant to venetoclax than those with wild-type TP53 (e.g., SUDHL5 and OCI-Ly10), TP53 mutation is associated with reduced venetoclax sensitivity in AML and CLL [40,41]. The gene discussed is TP53; the disease is acute myeloid leukemia.